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Summary
Research in cancer development has led to the new treatment strategies based on gene 
and protein changes in cells that cause cancer. Such targeted drugs work differently than 
standard chemotherapy agents, and have different and usually less severe side effects. 
Targeted chemotherapies have, however, enormous cutaneous adverse events which 
may lead to poor adherence, dose interruption and discontinuation of these therapeutic re-
gimens. Skin changes have a significant influence on the quality of life of affected patients.
In colorectal cancer, several targeted drugs are currently employed. Agents administe-
red in colorectal cancer that have resulted in significant cutaneous side effects include pri-
marily the epidermal growth factor receptor inhibitors (EGFRIs) and capecitabine. 
Common EGFRIs dermatologic adverse events are acneiform rash and xerosis. Less com-
mon findings are paronychia, regulatory abnormalities of hair growth, maculopapular rash, 
mucositis and postinflammatory hyperpigmentation. Management of skin rash should be 
individualized for each patient, depending on the type, severity and location of the skin 
toxicity caused by EGFRIs.
Hand-foot syndrome (HFS), or palmar-plantar erythrodysestesia, is the most common 
dose-limiting toxicity and the only clinically significant adverse event that frequently occurs 
with capecitabine compared to 5-FU/leucovorin intravenous administration.
Cutaneous side effects affect compliance, patients’ quality of life, as well as the therapy 
regimen. 
It is important to recognize and treat, as well as to administer efficacious prophylactic 
and therapeutic measures in a timely manner. This enables regular administration of adequ-
ate chemotherapy regimens and prolongs lives of oncology patients.
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Studies have demonstrated a positive correlation between treatment efficacy and cu-
taneous side effects for both EGFRI and capecitabine. Therefore, cutaneous side effects can 
serve as a predictor of improved survival in these patients.
Since frequency and severity of skin lesions are dose-dependent, a gradual increase in 
dose until a cutaneous side-effect develops might be a good strategy to maximize the efficacy 
of EGFRIs and capecitabine. 
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INTRODUCTION
Research in cancer development has led to the new treatment strategies 
based on gene and protein changes in cells that cause cancer. Such targeted 
drugs work differently than standard chemotherapy agents, and have different 
and usually less severe side effects. In colorectal cancer several targeted drugs 
are currently employed. Vascular endothelial growth factor (VEGF) inhibitors 
include bevacizumab (Avastin®) and ziv-aflibercept (Zaltrap®). Epidermal 
growth factor receptor (EGFR) targeted drugs include cetuximab (Erbitux®) and 
panitumumab (Vectibix®). Rigorafenib (Stivarga®) is another targeted drug for 
advanced colorectal cancer and is known as kinase inhibitor [1]. 
Capecitabine is an oral fluoropyrimidine widely administered in patients 
with colorectal cancer [2].
Targeted chemotherapies have, however, enormous cutaneous adverse 
events which may lead to poor adherence, dose interruption and discontinua-
tion of these therapeutic regimens. Skin changes have a significant influence on 
the quality of life of affected patients [3]. 
Agents administered in colorectal cancer that result in significant cutaneous 
side effects include primarily EGFRIs and capecitabine. Therefore, this article 
will in particular focus on side effects occurring in these two therapy regimens.
EGFRI 
The epidermal growth factor receptor (EGFR) is overexpressed or dysregu-
lated in several solid tumors including lung, head and neck and colorectal car-
cinoma. Dysregulated EGFR may result in uncontrolled cell growth, prolifera-
tion and angiogenesis and is associated with poorer prognoses, manifested by 
increased metastatic potential and poorer overall survival (OS). Thus, EGFR is 
an ideal target for antitumor therapy. EGFR inhibitors (EGFRIs) include tyrosin 
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kinase inhibitors (erlotinib and gefitinib) and the monoclonal antibodies (pa-
nitumumab, cetuximab) that competitively bind to the extracellular domain of 
EGFR and block cytoplasmic-domain phosphorilation. EGFR blockade results 
in growth arrest and apoptosis in cells dependent on EGFR for survival through 
the inhibition of downstream pathways [4,5].
As a class, EGFRIs are characterized by cutaneous adverse effects, mainly 
papulopustular reactions involving skin. In addition to leaving skin vulnerable 
to bacterial overgrowth and serious infection, skin rash can lead to dose modi-
fication or treatment discontinuation, potentially affecting the overall clinical 
benefits of the therapy [5].
EGFRI – cutaneous side effects 
Pathobiology of EGFRI – associated cutaneous toxicity 
EGFRIs affect basal keratinocytes which results in some of the cutaneous 
side effects. Inhibition of the EGFR mediated signaling pathways induces in ke-
ratinocytes growth arrest and apoptosis, decreasing cell migration, increasing 
cell attachment and differentiation and stimulating inflammation. All of these 
result in distinctive cutaneous manifestations [4].
Due to the interference of epidermal growth factor signaling in the skin, cu-
taneous adverse events are common. Common dermatologic adverse events are 
acneiform rash and xerosis [3].
Acneiform (papulopusutlar) rash 
Acneiform rash is the most common EGFRI cutaneous adverse event report-
ed in 50-100% of clinical trials. It can appear between day 2 to week 6 follow-
ing initiation of therapy. Eruption is present in seborrhoic areas and resembles 
lesions of acne, but comedones, primary acne lesions, are absent. Such lesions 
can be painful, burning, irritating or pruritic. The periorbital region as well as 
palms and soles are usually spared [3]. Figures 1-3 present some of our patients 
receiving EGFRI with characteristic acneiform lesions. Acneiform rash is con-
sistent with NCI CTCAE, version 4.0, graded into 5 grades, as shown in table 1 
[6]. Lynch et al. described the clinical severity of acneiform rash as presented in 
table 2 [7].
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Figures 1.-3.  Acneiform rash in patients on EGFRI therapy
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Table 1. Acneiform rash grading*
Grade Clinical status
1 Papules and/or pustules covering <10%BSA (body surface area), which may or may 
not be associated with symptoms of pruritus or tenderness
2 Papules and/or pustules covering 10-30% BSA, which may or may not be associated 
with symptoms of pruritus or tenderness; associated with psychosocial impact; 
limiting instrumental ADL (activities of daily life)
3 Papules and/or pustules covering >30% BSA, which may or may not be associated 
with symptoms of pruritus or tenderness; limiting self-care ADL; associated with local 
superinfection with oral antibiotics indicated
4 Papules and/or pustules covering any % BSA, which may or may not be associated 
with symptoms of pruritus or tenderness and are  associated with extensive 
superinfection with IV antibiotics indicated; life-threatening consequences
5 Death
*according to NCI CTCAE, version 4.0. [6]




No impact on ADL
No sign of superinfection
Moderate Generalized
Mild symptoms (pruritus, tenderness)
Minimal impact on ADL
No sign of superinfection
Severe Generalized
Severe symptoms (pruritus, tenderness)
Significant impact on ADL
Potential for superinfection
*according to Lynch et al. [7]
Acneiform rash treatment 
Prophylactic treatment of acneiform rash: based on randomized clinical tri-
als, tetracycline and tetracycline class antibiotics (doxycycline 100 mg bid) for 
the first 6 weeks are recommended [7-11]. Hydrocortisone 1% combined with 
moisturizer, avoidance of prolonged sun exposure and application of sunscreen, 
although lacking evidence, should still be considered as general patient recom-
mendations [3,8].
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Reactive treatment 
If patients develop EGFRI-associated toxicity, treatment based on clinical se-
verity of the rash is suggested. In mild toxicities only topical therapy such as hy-
drocortison (1% or 2,5%) cream or clindamycin (1%) gel is recommended. There 
is no need to alter the EGFRI dosage [7].
In patients who develop moderate toxicity, local therapy as mentioned above 
is recommended, with an addition of tetracycline class of antibiotics. Doxycycline 
2x100 mg bid is mainly advisable due to its more favorable safety profile com-
pared to minocycline [7].
In cases of severe toxicity, reduction in the EGFRI dose is recommended. 
Therapy recommended for moderate toxicity should be administered, with an 
addition of a methyprednisolone dose pack. If toxicity does not diminish within 
2-4 weeks of therapy interruption of EGFRI treatment is recommended accord-
ing to the prescribing information [7]. 
In order to avoid dermal toxicity as well as increased risk for bacterial or vi-
ral superinfection, pulsed application of topical corticotsterods is advisable [7].
EGFRI induced acneiform rash differs from acne vulgaris, therefore topical 
therapy advised for this disease, such as topical retinoids or benzoyl peroxide, 
is not recommended [12].
Xerosis cutis 
Xerosis cutis is the second most common cutaneous adverse event from EGFRI, 
which occurs in over 35% in most reports. It is presented as a dry, itchy scaly area 
of the skin and can progress to painful fissuring and eczema (eczema cracquelée). 
It may take place at sites where papulopustules have developed; however, more 
widespread involvement usually occurs. Symptomatic treatment including use of 
emolients is advisable [3,12].
In case of occurrence of fissures, which mainly develop on the hands and 
feet, creams or ointments with dexpanthenol are used to soften the skin and 
enhance healing [12].
Less common findings are paronychia, regulatory abnormalities of hair growth, 
maculopapular rash, mucositis and postinflammatory hyperpigmentation [3]. 
Paronychia 
Paronychia is described in 5-20% of patients and usually develops after 1-2 
months. In severe cases ingrown nail, periungual abscess and pyogenic granu-
loma-like lesions can occur [3]. 
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Management strategies include wearing comfortable shoes, trimming nails 
but avoiding aggressive manicuring, and wearing gloves while cleaning. Topical 
corticosteroids and anti-inflammatory dose tetracyclines to decrease periungual 
inflammation and antibiotic soaks are advisable. Electrocautery, sliver-nitrate and 
nail avulsion are recommended to eliminate excessive granulation tissue [8]. 
Hair growth disturbances 
Abnormalities of hair growth occur infrequently and usually develop 2-5 
months after initiating EGFRI. Trichomegaly and facial hypertrichosis (hirsutism) 
can be seen after the first 1-2 months of therapy, and they tend to persist for the du-
ration of EGFRI therapy. Temporary or permanent hair removal may be advised. 
Aberrant eyelashes may lead to corneal irritation and ulceration. Trichomegaly 
can be treated with lash clipping every 2-4 weeks and referral to an ophthalmolo-
gist is indicated for patients with irritation or persistent discomfort [3,8].
Non-scarring alopecia may occur after 2-3 months of therapy. It may prog-
ress to diffuse alopecia and generally resolves after treatment discontinuation, 
although hair regrowth may be of varying quality. Minoxidil 2% and 5% may be 
used. Scarring alopecia has also been reported, and treatment options include 
topical corticosteroids (shampoos, creams and lotions), [8].
Mucositis 
Oral mucositis is rare in EGFRI treated patients and may present as erythema, 
aphthous-like stomatitis or superimposed upon those of radiation and conven-
tional chemotherapy. Prevention and treatment of oral complications include thor-
ough oral care, aggressive pain management with topical analgesics and systemic 
analgesics as needed, adequate nutritional support, radiation treatment planning 
that optimizes therapeutic index, benzydamine oral rinse [8]. 
Postinflammatory hyperpigmentation 
Postinflammatory hyperpigmentation occurs in approximately 10% of pa-
tients with acneiform rash. It is therefore recommended that patients take ap-
propriate sun protective measures while receiving EGFRIs [13]. 
Management of skin rash should be individualized for each patient, depending 
on the type, severity and location of the skin toxicity caused by EGFRIs [5].
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Patient should be referred to a dermatologist in following situations: 
1) If the skin toxicity does not improve within 1-2 weeks of treatment;
2) If the patient is severely symptomatic;
3) If the skin toxicity has an uncharacteristic appearance of distribution [5].
The effect of EGFRI and concomitant radiotherapy 
EGFRIs are very often administered concomitantly with radiotherapy. Ef-
fects can be divided into the early and late phases. In the early phase, when EG-
FRIs are introduced simultaneously with radiation compared to radiation alone, 
radiation dermatitis as well as EGFRI side effects increase. Skin eruption occurs 
predominantly in irradiated areas. This is due to synergistic cytotoxicity and the 
therapeutic response of to two agents [3].
In the late phase, however, prolonged radiation leads to the absence of skin 
toxicity to EGFRIs in the preirradiated area. The reason for this is depletion of 
basal layer stem cells due to apoptosis induced by radiation [3].
EGFRI efficacy and severity of skin rash 
It has been shown that the presence and severity of cutaneous side effects 
have a positive correlation with patient survival and tumor response. Since fre-
quency and severity of skin lesions are dose dependent, a gradual increase in 
dose until skin eruption develops may be a good strategy to maximize the ef-
ficacy of EGFRIs [3,7]. 
Capecitabine 
Capecitabine is registered for the treatment of several tumor entities including 
colorectal-, gastric- and breast cancer. It is an orally administered 5-fluorouracil 
(5-FU) prodrug designed to mimic the pharmacokinetics of infusional 5-FU [14].
It is generally well-tolerated , with hand foot syndrome beeing the only clini-
cal adverse event that commonly occurs with capecitabine treatment [2].
Hand-foot syndrome (HFS), or palmar-plantar erythrodysestesia is the 
most common dose-limiting toxicity and the only clinically significant adverse 
event that frequently occurs with capecitabine compared to 5-FU/leucovorin in-
travenous administration [2]. HFS incidence in patients receiving capecitabine is 
50-60%, while grade III toxicity appears in 10-17% of patients [15].
This side effect is common with administration of some other cytotoxic drugs 
such as continuous 5-FU infusion, doxorubicin, cytarabine or docetaxel [16].
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The mechanism responsible for HFS is unknown, although it is frequent-
ly considered as a type of inflammation [15]. Recent data indicate that HFSR 
(Hand-foot-skin-reaction) may be caused by a reduction in the oxidative poten-
tial of the skin due to intensive radical formation [14]. 
The risk factors of HFS have been reported to be older age, female sex, im-
proved performance, continuous infusion of chemotherapy agents as well as 
inclusion of docetaxel in chemotherapy regimen [15].
Patients usually present with a prodrome of dysesthesia affecting palms and 
soles. The condition progresses in a few days to burning pain sensations to-
gether with well-defined swelling and erythema. If the drug dose is not adjusted 
there may be skin breakdown, desquamation, bullous formation or secondary 
infections. This is the reason why HFS can lead to reduced compliance and qual-
ity of life [2]. Clinical aspects of hand foot syndrome in our patients are shown 
in Figures 4-7. The hand-foot syndrome grading scale is shown in Table 3 [6]. 
Treatment-options for HFS are described in Table 4 [2].
Figures 4.-7.  Hand foot syndrome in patients receiving capecitabine.
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Table 3. Hand-foot syndrome grading*
Grade Clinical status
1 Minimal skin changes or dermatitis ( erythema, edema, hyperkeratosis) without pain
2 Skin changes (peeling, blisters, bleeding, edema or hyperkeratosis) with pain, limiting instrumental ADL
3 Severe skin changes (peeling, blisters, bleeding, edema, hyperkeratosis) with pain; limiting self-care ADL
*according to NCI CTCAE, version 4.0.[6]
Table 4. Management of the hand- foot syndrome*
Grade I Maintain doseApply skin barrier cream and apply MEBO (moist exposed burn ointment)
Grade II










Avoid extremes in temperature, pressure and friction of hand and foot
Cooling the hand and foot
Cushioning sore skin
Keeping the skin exposed to air
Preventing excess sweating
*according to Son et al [2]
Zhang et al. demonstrated in a single-center, prospective, randomized phase 
II trial that celecoxib (COX-2 inhibitor) can prevent capecitabine-related hand 
foot syndrome in stage II and III colorectal cancer patients [15].
Several studies confirmed that HFSR is a predictor of improved survival in 
patients with colorectal cancer [14,17,18]. A study by Hofheniz et al. indicates 
that the development of HFSR may be regarded as an independent clinical pre-
dictor of improved survival in patients with colorectal cancer regardless of the 
time point of HFSR development. Testing individual dose optimization or titra-
tion of capecitabine according to development HFSR may be an appealing strat-
egy for future studies [14].
Azuma et al. confirmed significant association between the hand-foot syn-
drome and the efficacy of capecitabine in patients with metastatic breast cancer 
[19].
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CONCLUSION 
Cutaneous side effects affect compliance, patients’ quality of life, as well as 
the therapy regimen. 
It is important to recognize and treat as well as to administer efficacious 
prophylactic and therapeutic measures in a timely manner. This enables regular 
administration of adequate chemotherapy regimens and prolongs the lives of 
oncology patients.
Studies have demonstrated a positive correlation between treatment efficacy 
and cutaneous side effects for both EGFRI and capecitabine. Therefore, cutane-
ous side effects can serve as a predictor of improved survival in these patients.
Since frequency and severity of skin lesions are dose-dependent, a gradual 
increase in dose until skin side-effect develops may be a good strategy to maxi-
mize the efficacy of EGFRIs and capecitabine. 
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Sažetak
Kožne nuspojave u bolesnika na ciljanoj terapiji raka kolorektuma
Istraživanja nastanka zloćudnih tumora dovela su do novih vrsta liječenja koje se za-
snivaju na promjenama gena i proteina u stanicama zloćudnih tumora. Takvi ciljani lijekovi 
imaju drugačiji mehanizam djelovanja od standardnih citostatika, te obično blaže nuspojave.
Ciljani lijekovi međutim imaju značajne nuspojave na koži koje mogu dovesti do slabije 
suradljivosti bolesnika, izostavljanja pojedinačne doze ali i prekida liječenja. Promjene na 
koži znatno utječu na kvalitetu života bolesnika.
U liječenju kolorektalnog karcinoma primjenjuje se nekoliko ciljanih lijekova. Od njih 
značajne nuspojave na koži imaju inhibitori epidermalnog čimbenika rasta (EGFRI), te ka-
pecitabin.
Česte dermatološke nuspojave EGFRI su akneiformni osip i suhoća kože, dok su manje 
česti paronihija, poremećaji u rastu dlaka, makulopapulozni osip, mukozitis i postinflama-
torne hiperpigmentacije. Liječenje nuspojava na koži treba biti prilagođeno svakom bolesni-
ku, ovisno o vrsti, težini i mjestu nastanka promjena.
Hand-foot syndrom (HFS, sindrom šaka i stopala) ili palmo-plantarna eritrodizestezija je 
najčešća toksičnost koja ograničava doziranje lijeka i jedina klinički značajna nuspojava koja 
se često javlja tijekom liječenja kapecitabinom u usporedbi s intravenskom primjenom 5-FU/
leukovorina.
Nuspojave na koži utječu na suradljivost, kvalitetu života bolesnika te provođenje tera-
pije.
Važno je na vrijeme prepoznati, liječiti te primijeniti učinkovite profilaktičke i terapijske 
mjere. Na taj način se osigurava redovita primjena odgovarajuće terapije i produžava život 
onkoloških bolesnika.
Kliničkim studijama je dokazana pozitivna povezanost učinkovitosti liječenja onkološ-
kih bolesnika i nuspojava na koži kod uporabe EGFRI i kapecitabina. Stoga nuspojave na koži 
mogu poslužiti kao prediktor boljeg ishoda bolesnika.
Budući su učestalost i težina nuspojava na koži ovisne o dozi lijeka, postupno povišenje 
doze do pojave nuspojava na koži može biti dobar način povećanja učinkovitosti kako EGFRi 
tako i kapecitabina.
Ključne riječi: ciljana terapija; nuspojave na koži; kolorektalni karcinom.
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